Sunovion Pharma has entered into an exclusive license agreement with Novartis for the US commercialization rights to three approved medicines:
- Utibron Neohaler (indacaterol and glycopyrrolate) inhalation powder (27.5 mcg/15.6 mcg)
- Seebri Neohaler (glycopyrrolate) inhalation powder (15.6 mcg) and
- Arcapta Neohaler (indacaterol) inhalation powder (75 mcg)
All three therapies are indicated for the long-term, maintenance treatment of airflow obstruction in people with COPD. Under terms of the agreement, Sunovion has the exclusive rights to market the products in the US.
Utibron Neohaler and Seebri Neohaler received FDA approval in 2015 and Sunovion plans to bring them to market in 2017, the company said. Arcapta Neohaler has been available since 2012. Novartis, which will continue to manufacture the products, will continue to retain the commercialization rights outside of the US.
“Sunovion has a long-standing commitment to advancing respiratory health and to providing new treatment options for people with COPD,” said David Frawley, Executive Vice President and Chief Commercial Officer, Sunovion. “We are pleased to add Utibron Neohaler, Seebri Neohaler and Arcapta Neohaler to our respiratory portfolio as these will complement our existing products and allow us to provide a wide range of treatment options for people with COPD.”